Glenmark Pharmaceuticals has informed that it has attached media release on 21st December 2020 titled ‘Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg’ which is self explanatory.
The above information is a part of company’s filings submitted to BSE.